 |
 |
||||||
 |
Our customers' Feedback |
Your cart
$0.00 (0 items)
| |||||
Generic Sumatriptan - Imitrex
- FDA approved Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
Considering the information of three randomized, multicenter, double, blind clinical studies and a retrospective analysis of the medical documentation, FDA approved on October 7, 2011 Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
- The forming, development and monitoring of the pharmaceutical market in USA in September 2011
In spite of low rates and stagnation of industrial development, the pharmaceutical market shows a dynamical growth.
- Sildenafil citrate and pulmonary arterial hypertension
Pulmonary arterial hypertension Definition “pulmonary arterial hypertension” is related to a group of diseases characterized by: - Progressive increase in pulmonary vascular resistance; - Reduction in pulmonary bloodflow; - High pulmonary artery pressure; - Contractility of the heart right ventricle; - Right ventricular failure.
- Fruit and vegetables do not reduce overall cancer risk, review concludes
Eating lots of fruit and vegetables will do little to reduce your risk of developing cancer, according to a review of a decade of research involving more than a million people.
- Common painkillers could be linked to male reproductive disorder
The use of mild painkillers, such as paracetamol, in pregnancy – previously considered harmless to the baby in the womb – could be a major factor in the rise of male reproductive disorders, according to a study.
Our billing is certified by:
- OptiNose OKed for Phase III trial of nasal delivery tech - In-PharmaTechnologist.com
In-PharmaTechnologist.
- OptiNose enrolls first patient in Phase III intranasal technology trial - Pharmaceutical Business Review
OptiNose enrolls first patient in Phase III intranasal technology trialPharmaceutical Business ReviewOptiNose has enrolled the first patient in a Phase III study involving the intranasal delivery of Sumatriptan powder using its bi-directional technology.
- OptiNose to begin Phase III trials with intranasal technology - Pharmaceutical Business Review
OptiNose to begin Phase III trials with intranasal technologyPharmaceutical Business ReviewOptiNose, a drug delivery company, has filed an investigational new drug (IND) with the FDA to use sumatriptan delivered with its novel drug delivery technology, in December 2011.
- NuPathe Announces Allowance of Additional U.S. Patent Application for Its ... - MarketWatch (press release)
NuPathe Announces Allowance of Additional U.
- Zogenix to Present at Leerink Swann 2012 Global Healthcare Conference - MarketWatch (press release)
Zogenix to Present at Leerink Swann 2012 Global Healthcare ConferenceMarketWatch (press release)Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache.
|
| Copyright © 2005-2012 Canadian Pharmacy Canada Pharmacy, Canadian Online Pharmacy. www.canadianpharmacyltd.biz is an affiliate marketing website. |